Canada’s Competition Bureau has addressed growing concerns across the globe over the pharmaceutical industry’s use of patents to block competition, and its Commissioner, John Pecman, outlined how Canada will tackle the issue.
Pecman spoke at a conference this week on the topic of Global Antitrust Challenges for the Pharmaceutical Industry, focusing on the issue of patent litigation settlement agreements that delay the entry of cheaper, generic drugs. The agreements are known as pay-for-delay deals.
Pecman announced a white paper, “Patent Litigation Settlement Agreements: A Canadian Perspective” to address the role of the Bureau in the matter.
The Commissioner said the Bureau would review potentially anticompetitive pay-for-delay deals with a strong emphasis on blocking any abuse of dominance.
Full content: EIN News
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Uruguayan Antitrust Scrutiny Puts Major Meatpacking Deal Between Marfrig and Minerva on Hold
May 19, 2024 by
CPI
Alaska Airlines Seeks Dismissal of Consumer Lawsuit Over $1.9 Billion Hawaiian Airlines Buy
May 19, 2024 by
CPI
Idaho Attorney General Orders Split of Kootenai Health and Syringa Hospital
May 19, 2024 by
CPI
Court Rejects T-Mobile’s Appeal Bid in Antitrust Case Over Sprint Merger
May 19, 2024 by
CPI
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI